Tirzepatide vs Semaglutide: How to Read the Trial Numbers Before You Compare Them

If you're weighing tirzepatide vs semaglutide, you've probably seen headlines claiming one "beat" the other by a certain number of kilos. Those numbers come from studies, and studies are easy to misread. This guide shows you what to check before you trust a comparison, so you can ask better questions the next time you see one.

Why the two numbers you see online don't compare the way you think

Two trials can both report weight loss and still be very different experiments. They may enroll different people, run for different lengths of time, use different doses, and define success in different ways. Put their numbers side by side and you're comparing apples to oranges, even if both fruits look similar in the headline.

Start with the study names. SURMOUNT-1 and STEP-1 both looked at obesity, but they were separate programs with separate participants. SURPASS-2 focused on type 2 diabetes. Each study answered its own question, so a result from one doesn't automatically transfer to another.

Next, check the type of analysis. Many well-designed trials report results using intention-to-treat, which counts everyone assigned to a group, including people who stopped early. A per-protocol analysis counts only people who followed the plan closely. Per-protocol numbers often look better, so check which one a headline quotes.

Finally, separate averages from proportions. An average tells you the middle of the group's results, but a few people may have lost a lot while others lost very little. A proportion tells you how many people reached a specific target. For example, "a certain share of participants reached a set weight-loss goal" answers a different question than "average loss was X%." Both matter, and you should know which one you're reading.

The head-to-head trials, and what they actually tested

A head-to-head trial puts two drugs against each other in the same study, with the same enrollment rules and timeline. That design carries more weight than an indirect comparison, where researchers line up separate trials and try to adjust for their differences. Indirect comparisons can generate ideas, but they can't fully remove differences between populations.

Two direct studies matter most here. SURPASS-2 compared tirzepatide with semaglutide in adults with type 2 diabetes. SURMOUNT-5 compared tirzepatide with semaglutide in adults with obesity. Both are published in peer-reviewed journals and can be found on PubMed. Before you quote any figure, open the original article and confirm the publication year, the journal, the number of participants, the doses compared, the duration in weeks, and the primary endpoint.

Pay close attention to the doses, because the arms were not always identical. In some designs, tirzepatide was tested at several dose levels while semaglutide was tested at a fixed dose. That reflects a particular pairing of doses, not a universal verdict on either molecule. When someone says one drug won, ask which doses were compared. If you want a clear walkthrough of how to read these tables, our trial-reading guide on OzemBlog breaks down each section step by step.

Dose, titration, and why the top dose matters for the result

Neither drug starts at full strength. Titration means the dose begins low and climbs in steps, usually every four weeks, until it reaches the maintenance dose. The main purpose of this schedule is to reduce gastrointestinal side effects like nausea, which tend to hit harder when the body meets a higher dose all at once. The prescribing information on DailyMed describes this gradual increase for both products, so you can confirm the exact steps there.

The top dose used in a trial shapes its results. A study that reaches a higher maximum dose often shows larger average effects, but it tells you less about someone on a lower maintenance dose. Trial doses don't always match what people take in daily practice. A doctor may stop at a lower dose based on tolerance and response, and that changes what you can expect.

Check the Brazilian label before drawing conclusions. The Anvisa bulário at consultas.anvisa.gov.br lists current indications and recommended doses for each product, and those indications have changed over time. Both medicines are dosed once weekly. OzemBlog has already covered the titration schedule in more detail, so it makes a useful companion read while you compare doses.

Side effects and discontinuation rates in the trials

Trials report adverse events and how many people stopped treatment because of them. These numbers often tell you more about everyday experience than a headline weight-loss figure does. A drug that works well on paper but pushes most people to quit won't help much in practice.

Timing matters as much as frequency. Nausea often appears in the first weeks or after a dose increase, and for many people it fades as the body adjusts. Effects that persist for months, or that come with new symptoms, deserve a separate conversation with your doctor. When you read an adverse event table, check when events occurred, not just how often they appeared.

Open the trial article and find the discontinuation rate due to adverse events in each arm, then compare it with the placebo or comparator group. Cross-check those figures with the adverse event tables in the Portuguese bula, since trial populations can differ from Brazilian prescribing. Effects vary between people, and your doctor weighs each patient's history before recommending one option over another.

Questions to ask the doctor before choosing one

Bring a short list of questions to your appointment. Ask whether the medicine is approved for your main reason for treatment, whether it's indicated for type 2 diabetes, obesity, or both, and what your medical history says about safety. Mention every medication, supplement, and condition you have, because some combinations need extra attention.

Some answers are non-negotiable. Both labels list contraindications for people with a personal or family history of medullary thyroid carcinoma, and for people with multiple endocrine neoplasia type 2 (MEN2). Tell your doctor about either history, even if it's distant or in a relative you rarely hear about.

Doctors often weigh type 2 diabetes and obesity together in the same patient. If you have both, the decision may depend on glucose control, weight goals, cardiovascular risk, and practical factors, not only on which molecule showed the bigger number in a trial. The Brazilian Diabetes Society (SBD) and the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) publish guidance on treatment choices, so ask how those recommendations apply to you. Bring the studies with you, printed or summarized. A one-page sheet with trial names, doses, and primary endpoints gives the conversation a concrete starting point.

How to check a claim you read online before you trust it

Start with the source of the number. Who funded the study? Was it randomized? Was the comparison direct, or did someone line up two separate trials? And is the figure from a published study or from an advertisement? A number on a product page is a marketing claim until you find the paper behind it.

Next, search PubMed at pubmed.ncbi.nlm.nih.gov using the trial name, such as SURMOUNT-5 with tirzepatide and semaglutide. You can also look up the trial's NCT identifier on ClinicalTrials.gov. That record shows the registered design, the planned duration, and the primary outcome, so you can compare what was planned with what was published. Before you repeat any number, run this check. The verification checklist we keep on OzemBlog works as a quick filter for most claims.

Watch for red flags in posts from influencers and sales pages:

• Promises of a cure or permanent fat loss with no cited study.
• Numbers that come without a trial name, year, or journal.
• Testimonials presented as proof that a product works for everyone.

No medicine is a cure, and any claim that one is should raise your guard. The honest wording is that a treatment may help, which in Portuguese is pode ajudar, and it may not work the same way for everyone. Find the official dosing information in the Anvisa bulário before you act on anything you read.

What the numbers can and cannot tell you about your own result

Trials report averages for groups, not guarantees for individuals. Some participants lost far more weight than the average, some lost less, and a few stopped early. A published figure describes the group, and your result may land anywhere in that spread.

Weight, blood sugar, and tolerance also change from person to person. Your starting weight, kidney and liver function, eating habits, and other medications all shape how you respond. A study can't capture the details of your daily life, which is exactly why these numbers should start a conversation rather than end one.

Before you start, switch, or stop any treatment, talk to your doctor. Share the studies you've read, ask how they apply to your case, and let your doctor decide what makes sense for you. Good data helps you ask sharper questions, and that's the real payoff of reading it well.

FAQ

Is tirzepatide better than semaglutide?

In the direct head-to-head trials, tirzepatide produced greater average effects than semaglutide. Results still depend on the population, the doses, and the study length, so your doctor can tell you which option fits your situation.

Can I switch from Ozempic to Mounjaro on my own?

No. Switching involves dose planning and a review of your health history, so it should happen with a doctor who knows your case.

Where can I check the official dosing information in Brazil?

Search the product name in the Anvisa bulário at consultas.anvisa.gov.br. The current bula lists approved indications, recommended doses, and adverse event tables.

Why does the top dose in a trial matter?

The highest dose in a study shapes the average result. If you take a lower maintenance dose, your experience may differ from the trial figures, so always check which doses were compared.

Sources

• PubMed (NCBI/NLM), base de busca de artigos científicos
• ClinicalTrials.gov (National Library of Medicine)
• Anvisa, Consulta a Produtos (bulário eletrônico)
• DailyMed (National Library of Medicine), bulas de prescrição dos EUA
• Anvisa, portal oficial
• Sociedade Brasileira de Diabetes (SBD)
• Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica (ABESO)